Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 11, 2026
TickeronGET DAILY SIGNALS
STERIS plc (STE): Q4 Earnings Preview and What Investors Should Watch

STERIS plc (STE): Q4 Earnings Preview and What Investors Should Watch

Key Takeaways

  • Analysts expect Q4 fiscal 2026 revenue of approximately $1.60 billion, up about 8% year-over-year.
  • Consensus adjusted EPS estimate stands at $2.89, reflecting 5.5% growth from $2.74 in the prior-year quarter.
  • STERIS reaffirmed fiscal 2026 guidance for 8-9% revenue growth and adjusted EPS of $10.15-$10.30, factoring in tariff impacts.
  • Q3 results showed 9% revenue growth to $1.50 billion and adjusted EPS of $2.53, meeting expectations amid tariff headwinds.
  • Investors will focus on segment performance in Healthcare, Applied Sterilization Technologies (AST), and Life Sciences.
  • Historical post-earnings moves have been mixed, with positive reactions about 53% of the time over five years.

Earnings Context and Why It Matters

As STERIS plc (STE) wraps up its fiscal 2026 with this Q4 report—covering the quarter ended March 31, 2026—I'm keeping a close eye on how the company navigates ongoing demand for infection prevention and sterilization solutions in healthcare. STERIS reports on a fiscal calendar ending June 30 for Q1, September 30 for Q2, December 31 for Q3, and March 31 for Q4. From what I see, revenue growth has been fueled by volume increases, pricing actions, and strategic acquisitions, making this release pivotal for confirming guidance against an estimated $55 million pre-tax tariff hit. In my view, investors like us need to assess margin resilience here, especially with supply chain pressures and the gradual recovery in procedural volumes shaping valuations across the medical devices sector.

Earnings Expectations

Looking at the numbers, analysts are forecasting Q4 revenue of around $1.60 billion, marking roughly 8% growth from $1.48 billion a year ago. This fits squarely with the company's guidance for full-year 8-9% as-reported growth and 7-8% constant currency organic growth. The consensus adjusted EPS comes in at $2.89, a 5.5% rise from $2.74 in Q4 FY2025, which supports the full-year outlook of $10.15-$10.30 even with tariff pressures. One thing that stands out are the key metrics: procedure volumes in the Healthcare segment, utilization rates at Applied Sterilization Technologies (AST) for end-of-line medical device processing, and demand for consumables in Life Sciences.

For context, Q3 FY2026 (ended December 31, 2025) delivered $1.50 billion in revenue, up 9% year-over-year with 8% constant currency organic growth, and adjusted EPS of $2.53 that met expectations. Historically, STE has seen mixed post-earnings reactions—positive about 53% of the time over the past five years, with media strong performance on those up days. I also checked this using Tickeron’s AI Screener to gauge how the stock stacks up against peers on technical patterns and fundamentals leading into this report.

Market Reaction and Investor Sentiment

Sentiment heading into earnings feels cautiously optimistic to me. Shares of STE are down about 3% recently, trading around $207 amid broader market headwinds. Analysts hold a "Moderate Buy" rating, with price targets in the $275-$287 range that suggest roughly 30% upside potential. That said, risks like tariff costs exceeding $55 million or softer procedure volumes loom large; on the flip side, beats on guidance could trigger rallies, given those historical 6% median positive moves.

Forward Outlook and Key Factors to Monitor

Entering fiscal 2027, STERIS carries momentum from steady organic growth, but I'll be tracking how full-year results stack up against guidance. Confirming 8-9% revenue expansion and EPS around the $10.25 midpoint will be crucial, particularly as tariffs squeeze margins.

Key areas to watch include recovery in the Healthcare segment as elective procedures stabilize, AST capacity expansions to handle rising device sterilization needs, and ongoing strength in Life Sciences from biopharma consumables. Updates on tariff mitigation strategies, supply chain costs, and currency impacts—assumed neutral—will matter too.

Longer term, M&A activity and guided free cash flow of $850 million should continue supporting dividends and buybacks. The post-COVID emphasis on infection control strengthens STERIS's positioning, though hospital capital spending and competitive pressures deserve monitoring.

Why I Rely on Tickeron’s AI Screener

In my own research and trading process, I’ve found Tickeron’s AI Screener invaluable for cutting through the noise. This AI-powered tool lets me scan thousands of stocks and ETFs using customizable filters on technical patterns, fundamentals, trends, volatility, and AI signals—spotting trade ideas, breakouts, and opportunities far faster than manual methods. It’s become a staple for comparing names like STE to industry peers efficiently.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: STE

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


STE sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for STE moved above the 200-day moving average on November 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

STE moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for STE crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 41%.

Following a +1.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where STE advanced for three days, in 155 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.

The Aroon Indicator entered an Uptrend today. In 101 of 203 cases where STE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.

Bearish Trend Analysis

The 10-day RSI Indicator for STE moved out of overbought territory on November 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 21 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 68 cases where STE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.

The Moving Average Convergence Divergence Histogram (MACD) for STE turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 25 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

STE broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. STE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.413) is normal, around the industry mean (4.142). P/E Ratio (30.693) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.760) is also within normal values, averaging (11.253). Dividend Yield (0.011) settles around the average of (0.011) among similar stocks. P/S Ratio (3.423) is also within normal values, averaging (40.124).

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of surgical and other medical supplies

Industry MedicalNursingServices

Industry
Medical Specialties
Address
70 Sir John Rogerson's Quay
Phone
+353 12322000
Employees
17937
Web
https://www.steris.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.